Report: Price Hikes for Top Part D Drugs Far Outpace Inflation

Mar 28, 2018 - 02:58 PM

The price of the 20 most prescribed brand-name drugs in the Medicare Part D program increased an average 12% per year between 2012 and 2017, about 10 times more than the average annual rate of inflation, according to a report released this week by Sen. Claire McCaskill (D-MO), ranking member of the Senate Homeland Security and Governmental Affairs Committee. Total price increases for the 20 drugs ranged from 31% to 477% over the five-year period, with six of the drugs more than doubling in price, based on the annual weighted average wholesale acquisition cost. “These findings underscore the need for further investigation by the committee and other policymakers into dramatic price spikes and their impact on health care system costs and financial burdens for the growing U.S. senior population,” the report states.

Related News Articles

Headline
KFF: Medicare spent 27% more for people who disenrolled from MA than those continuously in Traditional Medicare
An analysis by KFF released last week found that in 2022, Medicare spent 27% ($2,585) more, on average, for individuals covered by Traditional Medicare after…
Headline
Bipartisan letter calling for prevention of Medicaid DSH cuts gets signatures from 182 members of Congress
A House Dear Colleague letter calling on House leadership to address scheduled Medicaid Disproportionate Share Hospital payment cuts received signatures from…
Headline
AHA responds to Medicare $2 Drug List Model request for information
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
AHA supports physician reimbursement, alternative payment model incentives in comments to MedPAC
In comments Dec. 9 to the Medicare Payment Advisory Commission, the AHA shared its views on physician fee schedule payments, advanced alternative payment model…
Headline
CMS releases proposed rule for 2026 Medicare Advantage, prescription drug plans
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026.…
Headline
AHA comments on CMS’ FY 2025 IPPS low wage policy
The AHA commented Nov. 26 on the Centers for Medicare & Medicaid Services’ hospital inpatient prospective payment system interim final action on revising…